ARTICLE | Translation in Brief
Stabilizing mutant proteins
NIBR, UBC’s allosteric MALT1 stabilizers for mutation-driven immunodeficiency
February 12, 2019 1:42 PM UTC
A team from Novartis Institutes for BioMedical Research (NIBR) and University of British Columbia has hit upon a strategy for treating diseases caused by loss-of-function protein mutations: target allosteric pockets on the mutant proteins to stabilize them.
The team showed the strategy worked on the W580S mutation of MALT1, which causes a form of immunodeficiency, and thinks it can apply to other proteins and diseases...
BCIQ Company Profiles
BCIQ Target Profiles
Mucosa associated lymphoid tissue lymphoma translocation gene 1 (MALT1)